Cyclo Therapeutics Stock News

Pre-open movers U.S. stock futures traded mixed in early pre-market trade after closing mostly flat in the prior session. Investors are awaiting earnings results from Lowe`s Companies Inc (NYSE: LOW

Some of the stocks that may grab investor focus today are: Wall Street expects Lowe`s Companies Inc (NYSE: LOW) to report quarterly earnings at $2.35 per share on revenue of $21.99 billion before t

The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) fell by over 15% pre-market today. This is why it happened.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the pricing of its previously announced underwritten public offering of 1,950,000 shares of its common stock at a public offering price of $6.00 per share. Gross proceeds from the offering, bef

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) (Cyclo Therapeutics of the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering ma

Cyclo Therapeutics (NASDAQ:CYTH) released its quarterly earnings data on Sunday. The company reported ($0.60) EPS for the quarter, beating the Zacks consensus estimate of ($0.67) by $0.07, MarketWatch Earnings reports. Cyclo Therapeutics had a negative net margin of 1,218.88% and a negative return on equity of 132.86%. Shares of NASDAQ:CYTH traded up $0.18 during trading []

Cyclo Therapeutics (NASDAQ:CYTH) released its earnings results on Sunday. The company reported ($0.60) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($0.67) by $0.07, MarketWatch Earnings reports. Cyclo Therapeutics had a negative return on equity of 132.86% and a negative net margin of 1,218.88%. Shares of Cyclo Therapeutics stock traded []

(RTTNews) - Shares of Cyclo Therapeutics, Inc. (CYTH) gapped up more than 5% on Tuesday morning. Today, the company said it has submitted investigational new drug (IND) application to the FDA for a Phase 2 study of Trappsol Cyclo for the treatment of early Alzheimer''s Disease (AD). The Company''s Trappsol Cyclo, an orphan drug designated

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changin

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for p